Market Research Logo

Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market 2015-2019

Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market 2015-2019

About CINV

CINV is one of the most dreaded adverse effects of chemotherapy. It often leads to the postponement or refusal of potentially curative chemotherapy treatment for cancer. This nausea and vomiting, associated with chemotherapy regimen, affects the quality of life of an individual.

The neurotransmitters in CINV are dopamine, 5-HT3, substance P, and endocannabinoids. CINV can be caused by the stimulation of vomiting center by the abdominal vagal afferents or by the direct stimulation of CTZ in the area postrema. The risk of development of CINV changes with the use of different types of chemotherapy regimens such as high, moderate, low, and minimal risk.

Based on the type of CINV, different treatment regimens are prescribed. The classes of drugs used in the treatment of CINV are 5-HT3 receptor antagonists, NK1 receptor antagonists, corticosteroids, dopamine antagonists, benzodiazepines, and cannabinoids. Most of the drugs used in the treatment are helpful in the prevention of vomiting but show less effect in treating nausea.

Technavio's analysts forecast the global chemotherapy induced nausea and vomiting drugs market to grow at a CAGR of 4.9% over the period 2014-2019.

Covered in this report

The report covers the present scenario and the growth prospects of the global CINV drugs market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various branded therapies and generics along with the drugs used as off-label for the treatment of CINV.

Technavio's report, Global CINV Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global CINV drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.Key regions

  • Americas
  • APAC
  • EMEA
Key vendors
  • GlaxoSmithKline
  • Helsinn
  • Heron Therapeutics
  • Merck & Co
  • Tesaro
Other prominent vendors
  • Acacia Pharma
  • Aphios
  • Barr Laboratories
  • Baxter Healthcare
  • Eisai
  • Especificos Stendhal
  • F.Hoffmann La Roche
  • Mundipharma
  • Mylan Pharmaceuticals
  • OPKO Health
  • Orchid Healthcare
  • Otsuka Pharmaceutical
  • ProStrakan
  • Sandoz (Novartis)
  • Solvay Pharmaceuticals
  • Specialised Therapeutics Australia
  • Sun Pharma
  • Taiho Pharmaceutical
  • Teva Pharmaceuticals
Market driver
  • Increase in incidence and prevalence of cancer
  • For a full, detailed list, view our report
Market challenge
  • Complex physiology of CINV
  • For a full, detailed list, view our report
Market trend
  • Increased use of combination therapies
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market 2015-2019.

Technavio recognizes the following companies as the key players in the Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market: GlaxoSmithKline, Helsinn, Heron Therapeutics, Merck & Co and Tesaro.

Other Prominent Vendors in the market are: Acacia Pharma, Aphios, Barr Laboratories, Baxter Healthcare, Eisai, Especificos Stendhal, F.Hoffmann La Roche, Mundipharma, Mylan Pharmaceuticals, OPKO Health, Orchid Healthcare, Otsuka Pharmaceutical, ProStrakan, Sandoz (Novartis), Solvay Pharmaceuticals, Specialised Therapeutics Australia, Sun Pharma, Taiho Pharmaceutical and Teva Pharmaceuticals.

Commenting on the report, an analyst from Technavio’s team said: “One major trend in the market is individuals tend to develop resistance to monotherapies over a period of time, resulting in the increased preference for combination therapies. These combination therapies have a better safety and efficacy profile, increasing their preference for treating CINV.”

According to the report, one key driver of this market is patent expiries result in the loss of market exclusivity of a drug, leading to a rapid decline in its sales. This leads to the market entry of generic forms that have a similar efficacy and safety profile as the branded drug and are available at low prices. The patents of most of the CINV drugs have either expired or are set to expire by the end of the forecast period.

Further, the report states that one of the major challenges in the market is off-label drugs are unapproved medications, but show efficacy in the treatment of the condition. Many off-label drugs are used to manage CINV. Corticosteroids, such as dexamethasone, are commonly used to treat CINV.

Companies Mentioned

GlaxoSmithKline, Helsinn, Heron Therapeutics, Merck & Co, Tesaro, Acacia Pharma, Aphios, Barr Laboratories, Baxter Healthcare, Eisai, Especificos Stendhal, F.Hoffmann La Roche, Mundipharma, Mylan Pharmaceuticals, OPKO Health, Orchid Healthcare, Otsuka Pharmaceutical, ProStrakan, Sandoz (Novartis), Solvay Pharmaceuticals, Specialised Therapeutics Australia, Sun Pharma, Taiho Pharmaceutical, Teva Pharmaceuticals

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
  • Product profiles
    • Zofran
    • Aloxi/Onicit/Paloxi
    • Akynzeo
    • EMEND
  • Disease overview
    • Understanding the disease
    • Pathophysiology
    • Types of CINV
      • Table Types of CINV
    • Causes
      • Table Causes of emesis
    • Risk factors
      • Table Chemotherapeutics-related emetic risk
    • Management
      • Table Management of CINV
    • Economic burden
  • Regulatory guidelines on CINV
    • Table Regulatory guidelines by ASCO, ESMO, MASCC, and NCCN for CINV treatment
  • Pipeline analysis
    • Table CINV drugs: Pipeline portfolio
  • Market landscape
    • Market overview
    • Market size and forecast
      • Table Global CINV drugs market 2014-2019 ($ millions)
    • CINV drugs market in US
      • Table CINV drugs market in US 2014-2019 ($ millions)
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by route of administration
    • Table Global CINV drugs market segmentation by route of administration
    • Oral
    • Parenteral
    • Transdermal
  • Market segmentation by disease onset
    • Table Global CINV drugs market segmentation by disease onset
    • Acute CINV
    • Delayed CINV
    • Anticipatory CINV
    • Breakthrough CINV
  • Market segmentation by pharmacological class of drug
    • Table Global CINV drugs market Segmentation by pharmacological class of drug
    • 5-HT3 receptor antagonists
    • NK1 receptor antagonists
    • Corticosteroids
    • Dopamine receptor antagonists
    • Benzodiazepines
    • Cannabinoids
  • Market segmentation by type of therapy
    • Table Global CINV drugs market segmentation by type of therapy
    • Monotherapy
    • Combination therapy
  • Geographical segmentation
    • Global CINV drugs market segmentation by geography
      • Table Global CINV drugs market segmentation by geography 2014
  • Market drivers
    • Table Major drivers of global CINV drugs market
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Table Major challenges in global CINV drugs market
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Table Major trends in global CINV drugs market
  • Vendor landscape
    • Competitive scenario
    • Market share analysis 2014
      • Table Merck: YoY growth and revenue of EMEND 2011-2014 ($ millions)
    • Other prominent vendors
  • Key vendor analysis
    • GlaxoSmithKline
    • Helsinn
    • Heron Therapeutics
    • Merck
    • TESARO
  • Appendix
    • List of abbreviation
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report